Medicago’s research, and product and process development activities are centralized in Quebec City, the most European city in North America, where the company operates three sites throughout the city.
Its 3,000 m2 pilot plant is located alongside a 1,100 m2 greenhouse, while its headquarters, which also houses laboratories, is perched above the city.
A new complex is currently under construction. The state-of-the-art facility, spreading out over 90,000 m2, will house the company’s new headquarters along with operations, R&D, production and all support functions. This new facility will be capable of providing up to 1 billion pandemic vaccine doses annually.